These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26384287)

  • 1. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
    Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
    Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and profiling of a selective and efficacious Syk inhibitor.
    Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
    J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
    Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
    ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.